An analysis of the COMPASS trial in patients with GFR ≥60 or <60 mL/min showed consistent treatment benefit of the combination of rivaroxaban 2.5 mg bd plus aspirin, vs aspirin alone.
New data of the ORION-3 trial demonstrate that twice a year dosing of the siRNA directed at PCSK9 mRNA inclisiran gives sustained and safe lowering of LDL-C by more than 50 percent for up to 3 years, on top of LDL-c lowering therapies.
A prediction model was developed based on RE-LY data, to assess the absolute treatment benefit and harm from dabigatran therapy in individuals with AF with readily available patient characteristics
ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.
LDL-c levels vary greatly among pediatric patients with genetically defined hoFH, and overlap exists between the LDL-c levels and phenotypes of severe heFH and hoFH.
An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.
Spin, defined as manipulation of language to potentially mislead readers, was identified in 57% of abstracts and 67% of main texts in CV RCTs that reported statistically non-significant results for primary outcomes.
In individuals without CVD history in the ARIC study, increase in troponin I, measured by a high sensitivity assay, was associated with ASCVD, global CVD, CHD, stroke, HF hospitalization, and all-cause mortality.
First-in-class firibastat, a selective and specific inhibitor of brain aminopeptidase A, safely reduced BP in hypertensive, overweight patients of multiple ethnic origins.
Tafamidis meglumine and tafamidis capsules have received FDA approval for treatment of cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM) in adults.
A mendelian randomization analysis in population-based cohorts assessed that lowering Lp(a) by 65.7 mg/dL yields a similar CHD event risk reduction as lowering LDL-c by 38.67 mg/dL
In women, longer total exposure to antibiotics in middle- and late adulthood was significantly associated with risk of CVD in later life, and antibiotic use in middle adulthood with risk of CHD but not of stroke.